Emmaus Life Sciences Inc (EMMA)
0.11
+0.01
(+10.00%)
USD |
OTCM |
May 06, 16:00
Emmaus Life Sciences Cash from Operations (TTM): -0.862M for Sept. 30, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
September 30, 2023 | -0.862M |
June 30, 2023 | -1.874M |
March 31, 2023 | -1.632M |
December 31, 2022 | -5.073M |
September 30, 2022 | -5.885M |
June 30, 2022 | -3.291M |
March 31, 2022 | -1.986M |
December 31, 2021 | -1.254M |
September 30, 2021 | -0.208M |
June 30, 2021 | -4.491M |
March 31, 2021 | -8.26M |
December 31, 2020 | -2.451M |
September 30, 2020 | |
June 30, 2020 | |
March 31, 2020 | |
December 31, 2019 | |
September 30, 2019 | |
June 30, 2019 | -7.651M |
March 31, 2019 | -8.134M |
December 31, 2018 | -8.341M |
September 30, 2018 | -9.039M |
June 30, 2018 | -9.534M |
March 31, 2018 | -7.931M |
December 31, 2017 | -6.466M |
September 30, 2017 | -4.792M |
Date | Value |
---|---|
June 30, 2017 | -3.620M |
March 31, 2017 | -3.240M |
December 31, 2016 | -3.137M |
September 30, 2016 | -2.978M |
June 30, 2016 | -2.474M |
March 31, 2016 | -2.153M |
December 31, 2015 | -1.970M |
September 30, 2015 | -2.156M |
June 30, 2015 | -2.415M |
March 31, 2015 | -2.737M |
December 31, 2014 | -3.009M |
September 30, 2014 | -3.271M |
June 30, 2014 | -3.552M |
March 31, 2014 | -3.603M |
December 31, 2013 | -3.538M |
September 30, 2013 | -3.036M |
June 30, 2013 | -2.419M |
March 31, 2013 | -2.016M |
December 31, 2012 | -2.039M |
September 30, 2012 | -2.337M |
June 30, 2012 | -2.913M |
March 31, 2012 | -3.448M |
December 31, 2011 | -3.853M |
September 30, 2011 | -4.179M |
June 30, 2011 | -4.029M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-8.26M
Minimum
Mar 2021
-0.208M
Maximum
Sep 2021
-3.455M
Average
-2.451M
Median
Dec 2020
Cash from Operations (TTM) Benchmarks
AIM ImmunoTech Inc | -21.27M |
Perspective Therapeutics Inc | -36.91M |
Protalix BioTherapeutics Inc | -1.318M |
Electromed Inc | 4.872M |
Armata Pharmaceuticals Inc | -47.42M |